Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer
暂无分享,去创建一个
E. Jaffee | L. Coussens | elliot k fishman | Jin He | R. Burkhart | B. Blouw | T. Tsujikawa | Victoria Kim | May Tun Saung | T. Armstrong | N. Lokker | A. Blair | Stephen Muth | L. Zheng | Lei Zheng
[1] P. Philip,et al. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Paolo P. Provenzano,et al. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. , 2018, Cancer research.
[3] D. V. Von Hoff,et al. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression , 2018, Clinical Cancer Research.
[4] S. Lowe,et al. Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy , 2018, Immunity.
[5] Lei Zheng,et al. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Pierce,et al. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma , 2017, Cancer Immunology Research.
[7] R. Korn,et al. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours , 2017, British Journal of Cancer.
[8] M. Miyasaka,et al. Regulation of CCR7-dependent cell migration through CCR7 homodimer formation , 2017, Scientific Reports.
[9] Adam A. Margolin,et al. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.
[10] G. Miller,et al. Myeloid-derived suppressor cells and their role in pancreatic cancer , 2016, Cancer Gene Therapy.
[11] A. Biankin,et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma , 2016, Cancer cell.
[12] David S. Wishart,et al. Heatmapper: web-enabled heat mapping for all , 2016, Nucleic Acids Res..
[13] D. Weaver,et al. Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.
[14] J. Couchman,et al. Extracellular matrix component signaling in cancer. , 2016, Advanced drug delivery reviews.
[15] Umar Mahmood,et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.
[16] C. Iacobuzio-Donahue,et al. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer , 2015, Science Signaling.
[17] D. Pardoll. Cancer and the Immune System: Basic Concepts and Targets for Intervention. , 2015, Seminars in oncology.
[18] T. Ludwig,et al. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors , 2015, Cancer Immunology Research.
[19] R. Jain,et al. CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice , 2015, Hepatology.
[20] E. Jaffee,et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Caroline H. Diep,et al. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer , 2015, Clinical Cancer Research.
[22] E. Jaffee,et al. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors , 2015, Journal of immunotherapy.
[23] H. Shepard,et al. Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy , 2014, Molecular Cancer Therapeutics.
[24] Lei Zheng,et al. A preclinical murine model of hepatic metastases. , 2014, Journal of visualized experiments : JoVE.
[25] E. Eichler,et al. Evolutionary-new centromeres preferentially emerge within gene deserts , 2008, Genome Biology.
[26] R. Hruban,et al. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.
[27] Stephen A. Sastra,et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.
[28] H. Shepard,et al. Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[29] R. Jain,et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal‐derived factor 1 alpha/C‐X‐C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in mice , 2014, Hepatology.
[30] A. Rucki,et al. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. , 2014, World journal of gastroenterology.
[31] Derek S. Chan,et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.
[32] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[33] E. Jaffee,et al. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. , 2013, Gastroenterology.
[34] J. Taube,et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. , 2013, Journal of visualized experiments : JoVE.
[35] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[36] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[37] H. Shepard,et al. Effective targeting of the tumor microenvironment for cancer therapy. , 2012, Anticancer research.
[38] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[39] Carlos Cuevas,et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.
[40] V. Kosma,et al. Hyaluronan in human malignancies. , 2011, Experimental cell research.
[41] R. Jain,et al. CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? , 2011, Clinical Cancer Research.
[42] K. Lillemoe,et al. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.
[43] James O. Jones,et al. Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .
[44] P. O'Connor,et al. Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.
[45] S. Rosenberg,et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.
[46] Y. Iwakura,et al. CXC Chemokine Ligand 12 Promotes CCR7-Dependent Naive T Cell Trafficking to Lymph Nodes and Peyer’s Patches , 2009, The Journal of Immunology.
[47] I. C. Leão,et al. Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma , 2008, Clinical and translational science.
[48] E. Jaffee,et al. Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation , 2008, Clinical Cancer Research.
[49] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[50] F. Balkwill. Cancer and the chemokine network , 2004, Nature Reviews Cancer.
[51] Antonio Lanzavecchia,et al. Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.
[52] T. Oshikiri,et al. CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.
[53] E. Jaffee,et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.
[54] C. de Lange Davies,et al. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. , 1998, Cancer letters.
[55] M. Parmentier,et al. Genomic organization and promoter characterization of human CXCR4 gene 1 , 1998, FEBS letters.
[56] E. Jaffee,et al. Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. , 2017, Cancer research.
[57] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[58] Rogers Hj. The structure and function of hyaluronate. , 1961 .
[59] H. Rogers. The structure and function of hyaluronate. , 1961, Biochemical Society symposium.